ReviewCurrent treatment options in oncology2024
Impact of PSMA PET on Prostate Cancer Management.
Review in Current treatment options in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience.Clinical and translational radiation oncology · 2027Article
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
- Review
- Single-cell and spatial multi-omics reveal mechanistic insights of FOLH1+ endothelial cells in clear cell renal cell carcinoma.Journal of translational medicine · 2026Article
- Comparison of urinary bladder activity from [EJNMMI reports · 2026Article
- Article
- Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).Future oncology (London, England) · 2025Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Therapeutic Consequences ofCancers · 2025Article
- Utility ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Hematological toxicity of [EJNMMI radiopharmacy and chemistry · 2025Article
- Review
- Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study.Frontiers in oncology · 2025Article
- Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.Cancers · 2024Review
- Editorial: PET/CT and MRI in prostate cancer.Frontiers in oncology · 2024Article
- The contemporary management of prostate cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
opinion statementPSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.